Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly’s Omvoh receives FDA approval for ulcerative colitis treatment

October 27, 2023
Medical Communications Eli Lilly, FDA, Gastrointestinal tract, Omvoh, ulcerative colitis

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) infusion (300mg/15mL)/injection (100mg/mL) for …

News

China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment

October 26, 2023
Research and Development HIV, HIV/AIDS, NMPA, ViiV Healthcare, Vocabria

ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai shares new data for Leqembi for Alzheimer’s treatment

October 26, 2023
Research and Development Alzheimer's, Biogen, Eisai, Neurology, lecanemab

Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …

News

FDA approves Servier Pharmaceuticals’ new MDS therapy

October 25, 2023
Medical Communications FDA, Oncology, Servier Pharmaceuticals, myelodysplastic syndromes

The US Food and Drug Administration (FDA) has announced that it has approved Servier Pharmaceuticals’ Tibsovo (ivosidenib) for the treatment …

News

GSK shares new data for RSV vaccine Arexvy

October 25, 2023
Research and Development Arexvy, GSK, Immunology, RSV, Vaccine

GSK announced positive results from its phase 3 trial which assessed the immune response and safety of Arexvy, its respiratory …

News

AstraZeneca’s sBLA for FluMist Quadrivalent accepted by FDA

October 24, 2023
Medical Communications AstraZeneca, FDA, FluMist, Immunology, flu vaccine, sBLA

AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted for review its Supplemental Biologics License Agreement …

News
glsun-mall-9xmv81sz5fw-unsplash

Samsung Biologics and Kurma Partners announce collaboration for development and manufacturing of biologics

October 24, 2023
Business Services Kurma Partners, Pharmacy, Samsung BioLogics

Samsung Biologics and Kurma Partners have announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ …

News

Roche announces acquisition of Telavant

October 23, 2023
Business Services Gastrointestinal tract, Roche, Telavant

Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, a Roivant company, owned by …

News

AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC

October 23, 2023
Research and Development AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology

AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for …

News

Genentech shares data from phase 3 trials of Vabysmo for retinal vein occlusion treatment

October 10, 2023
Research and Development Genentech, Opthalmology, Vabysmo, phase 3 trial, retinal vein occlusion

Genentech has announced positive topline long-term results from its global phase 3 BALATON and COMINO trials which assessed extended treatment …

News

First patient dosed in Transgene and BioInvent’s phase 1 trial

October 10, 2023
Research and Development BioInvent, Oncology, Transgene, oncology, phase 1 trial

Transgene and BioInvent have announced that the first patient has been treated in the phase 1 part B clinical trial …

News

BMS acquires Mirati Therapeutics for $4.8bn

October 9, 2023
Business Services BMS, Mirati Therapeutics, Oncology, acquisition, bristol myers squibb, oncology

Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS …

News

GSK and Zhifei partner for shingles vaccine promotion in China

October 9, 2023
Medical Communications GSK, Immunology, Shingrix, Vaccine, Zhifei, shingles

GSK has announced that it has come to an exclusive agreement with Chingqing Zhifei Biological Products to co-promote GSK’s shingles …

News

Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment

October 6, 2023
Research and Development Nexviazyme, Pharmacy, Pompe disease, Sanofi

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the treatment of Pompe disease at …

News

FDA accepts Sun Pharma’s NDA for deuruxolitinib

October 6, 2023
Medical Communications Dermatology, FDA, NDA, SUun Pharma, deuruxolitinib

India-based pharma company Sun Pharmaceutical Industries has announced that the US Food and Drug Administration (FDA) has accepted its New …

News

FUJIFILM Diosynth Biotechnologies appoints Maja Pedersen as chief quality officer

October 6, 2023
Business Services Fujifilm, Fujifilm Diosynth Biotechnologies, Maja Pedersen, Pharmacy, appointment, chief quality officer

CEO and president of FUJIFULM Diosynth Biotechnologies Lars Petersen has appointed Maja Pedersen as chief quality officer, where she will …

Appointment

Janssen and Sanofi enter agreement for potential vaccine programme

October 5, 2023
Business Services Immunology, Janssen, Sanofi, e coli, vaccines

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with Sanofi for Janssen’s extraintestinal pathogenic …

News
diana-polekhina-zbsthwt9vlc-unsplash_2

Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine

October 5, 2023
Research and Development COVID-19, Immunology, Moderna, clinical trial, influenza, vaccines

Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational combination vaccine against influenza and …

News
louis-reed-pwckf7l4-no-unsplash_5

Sanofi and Teva partner for development of inflammatory bowel disease treatment

October 4, 2023
Medical Communications Crohn’s disease, Gastrointestinal tract, Sanofi, Teva, bowel disease, ulcerative colitis

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation of TEV’574, a treatment for …

News

Eli Lilly to acquire POINT Biopharma

October 4, 2023
Business Services Eli Lilly, Oncology, POINT Biopharma, acquisition, oncology

Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT to expand its pipeline of …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024